Immunophotonics, announced that they have successfully treated their first patient in the United States. Immunophotonics, headquartered in St. Louis, Missouri, is revolutionizing cancer treatment with their groundbreaking drug, IP 001.
Lu Alleruzzo, CEO Immunophotonics
“The treatment went well, as expected. The patient did very well during the treatment procedure,” CEO Lu Allerruzzo told bizblip. “And most importantly, in some of the early patients, we’re already seeing early signals off the drug doing what it’s intended to do… you work a decade to achieve that type of goal.”
Immunophotonics’ first drug, named IP-001 (for now), aims to transform traditional tumor destruction techniques into a systemic whole-body immunotherapy, providing targeted treatment for cancer patients wherever the disease may be.
Founded in 2008 in Columbia, MO the research startup is now based in St. Louis, Missouri, working primarily out of the BioGenerator Labs with access to animal research facilities, general labs, and resources for their clinical trials. In addition to their recent clinical success, Immunophotonics has amassed over 50 patents globally. According to Tracxn.com the company has raised more than $28 million in nine rounds, with the most recent Series B for $3.45M landing in Feb. 2023, following another Series B for $21.4M in April, 2022. Investors include Zubizoom, iSelect Fund, Johnson & Johnson Innovation, Cultivation Capital, and St. Louis Arch Angels.
In 2021 the company was awarded $400,000 by the National Institutes of Health, Department of Health and Human Services, to further develop the synthetic biopolymer, IP-001, “to potentiate asystemic immunotherapy via microwave thermal tumor ablation for treatment of Hepatocellular
carcinoma”.
Links:
